Home › Companies › ENANTA PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ENANTA PHARMACEUTICALS INC.’s Form 8-K, filed March 17, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of March 13, 2025: 5 items on ENANTA PHARMACEUTICALS INC.’s Form 8-K, filed March 17, 2025: 2 elected · 3 approved.
Significant dissent: 1 equity or compensation plan (26.3% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore ENANTA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are ENANTA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 17, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mark G. Foletta | 14,935,940 | -- | -- | 622,935 | 2,257,476 | 96% | Elected | — |
| Elect Director: Lesley Russell, MBChB, MRCP | 14,574,902 | -- | -- | 983,973 | 2,257,476 | 94% | Elected | — |
| 2. To Approve an Amendment to Our 2019 Equity Incentive Plan | 11,435,985 | 4,085,303 | 37,587 | -- | 2,257,476 | 74% | Approved | — |
| 4. To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers | 14,516,861 | 1,039,888 | 2,126 | -- | 2,257,476 | 93% | Approved | — |
| 5. To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2025 Fiscal Year | 17,740,127 | 72,357 | 3,867 | -- | 0 | 99.6% | Approved | — |
Source: ENANTA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on March 17, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
130 asset managers disclosed a vote on at least one ENANTA PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ENANTA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Lesley Russell
ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lesley Russell, MBChB, MRCP”): 14,574,902 for, 983,973 withheld, per its Form 8-K filed March 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following individuals as Class III directors of the Company:”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 4,459,467 for, 124,530 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,056,469 | 0 | 0 | 0 | For |
| BlackRock | 1,052,518 | 0 | 0 | 0 | For |
| Fidelity | 354,050 | 0 | 0 | 0 | For |
| Dimensional | 215,202 | 0 | 0 | 0 | For |
| Charles Schwab | 154,575 | 0 | 0 | 0 | For |
| Thrivent | 83,632 | 0 | 0 | 0 | For |
| JPMorgan | 76,659 | 0 | 0 | 0 | For |
| Equitable | 37,855 | 0 | 0 | 29,940 | Mixed |
| Columbia Threadneedle | 58,898 | 0 | 0 | 0 | For |
| TIAA | 55,049 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 45,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 37,640 | 0 | 0 | 0 | For |
| American Century | 37,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,896 | 0 | 0 | 0 | For |
| Nationwide | 31,281 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 30,612 | Withhold |
| Northern Trust | 22,348 | 0 | 0 | 0 | For |
| Prudential/PGIM | 22,320 | 0 | 0 | 0 | For |
| Lincoln Financial | 18,878 | 0 | 0 | 0 | For |
| GuideStone | 18,754 | 0 | 0 | 0 | For |
| Brighthouse | 17,641 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 11,800 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 11,417 | Withhold |
| Pacific Life | 10,024 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,949 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Mark G. Foletta
ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mark G. Foletta”): 14,935,940 for, 622,935 withheld, per its Form 8-K filed March 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following individuals as Class III directors of the Company:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 4,507,084 for, 76,913 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,056,469 | 0 | 0 | 0 | For |
| BlackRock | 1,052,518 | 0 | 0 | 0 | For |
| Fidelity | 354,050 | 0 | 0 | 0 | For |
| Dimensional | 215,202 | 0 | 0 | 0 | For |
| Charles Schwab | 154,575 | 0 | 0 | 0 | For |
| Thrivent | 83,632 | 0 | 0 | 0 | For |
| JPMorgan | 76,659 | 0 | 0 | 0 | For |
| Equitable | 37,855 | 0 | 0 | 29,940 | Mixed |
| Columbia Threadneedle | 58,898 | 0 | 0 | 0 | For |
| TIAA | 55,049 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 45,000 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 37,640 | 0 | 0 | 0 | For |
| American Century | 37,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,896 | 0 | 0 | 0 | For |
| Nationwide | 31,281 | 0 | 0 | 0 | For |
| Invesco | 30,612 | 0 | 0 | 0 | For |
| Northern Trust | 22,348 | 0 | 0 | 0 | For |
| Prudential/PGIM | 22,320 | 0 | 0 | 0 | For |
| Lincoln Financial | 18,878 | 0 | 0 | 0 | For |
| GuideStone | 18,754 | 0 | 0 | 0 | For |
| Brighthouse | 17,641 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 11,800 | 0 | 0 | 0 | For |
| Global X | 11,417 | 0 | 0 | 0 | For |
| Pacific Life | 10,024 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,949 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
74% Approved · of votes cast
Prior year: 52.1% for (March 6, 2024 meeting) ▲ 21.6 pts
Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR 2019 EQUITY INCENTIVE PLAN.
ENANTA PHARMACEUTICALS INC.’s own tally for this item (“2. To Approve an Amendment to Our 2019 Equity Incentive Plan”): 11,435,985 for, 4,085,303 against — passed, per its Form 8-K filed March 17, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 800,000 shares.”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 3,697,270 for, 886,755 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,006,078 | 50,391 | 0 | 0 | For |
| BlackRock | 1,052,518 | 0 | 0 | 0 | For |
| Fidelity | 341,541 | 12,509 | 0 | 0 | For |
| Dimensional | 0 | 215,202 | 0 | 0 | Against |
| Charles Schwab | 154,575 | 0 | 0 | 0 | For |
| Thrivent | 0 | 83,632 | 0 | 0 | Against |
| JPMorgan | 0 | 76,659 | 0 | 0 | Against |
| Equitable | 37,855 | 29,940 | 0 | 0 | Mixed |
| Columbia Threadneedle | 0 | 58,898 | 0 | 0 | Against |
| TIAA | 0 | 55,049 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 45,000 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 37,640 | 0 | 0 | 0 | For |
| American Century | 0 | 37,525 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 31,896 | 0 | 0 | Against |
| Nationwide | 1,776 | 29,505 | 0 | 0 | Mixed |
| Invesco | 0 | 30,612 | 0 | 0 | Against |
| Northern Trust | 0 | 22,348 | 0 | 0 | Against |
| Prudential/PGIM | 17,500 | 4,820 | 0 | 0 | Mixed |
| Lincoln Financial | 0 | 18,878 | 0 | 0 | Against |
| GuideStone | 0 | 18,754 | 0 | 0 | Against |
| Brighthouse | 0 | 17,641 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 11,800 | 0 | 0 | 0 | For |
| Global X | 11,417 | 0 | 0 | 0 | For |
| Pacific Life | 10,024 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,949 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
93% Approved · of votes cast
Prior year: 79.4% for (March 6, 2024 meeting) ▲ 13.9 pts
Description as filed by funds: To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.
ENANTA PHARMACEUTICALS INC.’s own tally for this item (“4. To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers”): 14,516,861 for, 1,039,888 against — passed, per its Form 8-K filed March 17, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,056,469 | 0 | 0 | 0 | For |
| BlackRock | 1,052,518 | 0 | 0 | 0 | For |
| Fidelity | 354,050 | 0 | 0 | 0 | For |
| Dimensional | 0 | 215,202 | 0 | 0 | Against |
| Charles Schwab | 154,575 | 0 | 0 | 0 | For |
| Thrivent | 83,632 | 0 | 0 | 0 | For |
| JPMorgan | 76,659 | 0 | 0 | 0 | For |
| Equitable | 67,795 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 58,898 | 0 | 0 | 0 | For |
| TIAA | 0 | 55,049 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 45,000 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 37,640 | 0 | 0 | 0 | For |
| American Century | 0 | 37,525 | 0 | 0 | Against |
| AIG/SunAmerica | 31,896 | 0 | 0 | 0 | For |
| Nationwide | 31,281 | 0 | 0 | 0 | For |
| Invesco | 0 | 30,612 | 0 | 0 | Against |
| Northern Trust | 22,348 | 0 | 0 | 0 | For |
| Prudential/PGIM | 17,500 | 4,820 | 0 | 0 | Mixed |
| Lincoln Financial | 15,200 | 3,678 | 0 | 0 | Mixed |
| GuideStone | 18,754 | 0 | 0 | 0 | For |
| Brighthouse | 17,641 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 11,800 | 0 | 0 | 0 | For |
| Global X | 11,417 | 0 | 0 | 0 | For |
| Pacific Life | 10,024 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,949 | 0 | 0 | 0 | For |
Fund voting reports, all 47 managers: 4,179,915 for, 404,082 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 1,065,788 | 0 | 0 | 0 | For |
| BlackRock | 765,294 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 477,524 | 0 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 434,316 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 371,254 | 0 | 0 | 0 | For |
| State Street | 355,649 | 117 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 348,749 | 0 | 0 | 0 | For |
| DE Shaw | 210,075 | 0 | 0 | 0 | For |
| Renaissance | 158,262 | 0 | 0 | 0 | For |
| Northern Trust | 156,166 | 0 | 0 | 0 | For |
| Charles Schwab | 154,575 | 0 | 0 | 0 | For |
| UBS | 0 | 148,960 | 0 | 0 | Against |
| Two Sigma | 115,272 | 0 | 0 | 0 | For |
| JPMorgan | 113,664 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 95,630 | 0 | 0 | 0 | For |
| Thrivent | 85,834 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 83,190 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 66,166 | 0 | 0 | 0 | For |
| Nuveen | 0 | 55,607 | 0 | 0 | Against |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 46,200 | 0 | 0 | Against |
| Invesco | 0 | 42,491 | 0 | 0 | Against |
| American Century | 0 | 37,525 | 0 | 0 | Against |
| Prudential/PGIM | 36,864 | 0 | 0 | 0 | For |
| Citadel | 36,184 | 0 | 0 | 0 | For |
| Dimensional | 0 | 34,549 | 0 | 0 | Against |
Institutional-manager reports, all 99 managers: 5,447,031 for, 372,769 against, 11,135 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation paid to our named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Thrivent | 0 | 0 | 0 | 0 | -- |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Columbia Threadneedle | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Nationwide | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| Brighthouse | 0 | 0 | 0 | 0 | -- |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| Pacific Life | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 46 managers: 4,331,320 1 year, 233,923 3 year. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 1,065,788 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| MARSHALL WACE, LLP | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 0 | 0 | 0 | -- |
| DE Shaw | 0 | 0 | 0 | 0 | -- |
| Renaissance | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| UBS | 0 | 0 | 0 | 0 | -- |
| Two Sigma | 0 | 0 | 0 | 0 | -- |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 0 | 0 | 0 | -- |
| Thrivent | 0 | 0 | 0 | 0 | -- |
| RA CAPITAL MANAGEMENT, L.P. | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| American Century | 0 | 0 | 0 | 0 | -- |
| Prudential/PGIM | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Connor, Clark & Lunn Investment Management Ltd. | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 94 managers: 1,076,901 for, 30 against, 4,179,019 1 year, 34,615 3 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.6% Approved · of votes cast
Prior year: 99.8% for (March 6, 2024 meeting) ▼ 0.2 pts
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2025 fiscal year.
ENANTA PHARMACEUTICALS INC.’s own tally for this item (“5. To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2025 Fiscal Year”): 17,740,127 for, 72,357 against — passed, per its Form 8-K filed March 17, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2025.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 48 asset managers below reported 4,583,856 for, 169 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,056,469 | 0 | 0 | 0 | For |
| BlackRock | 1,052,518 | 0 | 0 | 0 | For |
| Fidelity | 354,050 | 0 | 0 | 0 | For |
| Dimensional | 215,202 | 0 | 0 | 0 | For |
| Charles Schwab | 154,575 | 0 | 0 | 0 | For |
| Thrivent | 83,632 | 0 | 0 | 0 | For |
| JPMorgan | 76,659 | 0 | 0 | 0 | For |
| Equitable | 67,795 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 58,898 | 0 | 0 | 0 | For |
| TIAA | 55,049 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 45,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 37,640 | 0 | 0 | 0 | For |
| American Century | 37,525 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 31,896 | 0 | 0 | 0 | For |
| Nationwide | 31,281 | 0 | 0 | 0 | For |
| Invesco | 30,612 | 0 | 0 | 0 | For |
| Northern Trust | 22,348 | 0 | 0 | 0 | For |
| Prudential/PGIM | 22,320 | 0 | 0 | 0 | For |
| Lincoln Financial | 18,878 | 0 | 0 | 0 | For |
| GuideStone | 18,754 | 0 | 0 | 0 | For |
| Brighthouse | 17,641 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 11,800 | 0 | 0 | 0 | For |
| Global X | 11,417 | 0 | 0 | 0 | For |
| Pacific Life | 10,024 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 8,949 | 0 | 0 | 0 | For |
Showing the 25 largest of 48 asset managers. All 48 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 21,332,544 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.64% |
| 2 | BlackRock | 4.93% |
| 3 | Fidelity | 1.66% |
| 4 | Dimensional | 1.01% |
| 5 | Charles Schwab | 0.72% |
| 6 | Thrivent | 0.39% |
| 7 | JPMorgan | 0.36% |
| 8 | Equitable | 0.32% |
| 9 | Columbia Threadneedle | 0.28% |
| 10 | TIAA | 0.26% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 5.00% |
| 2 | BlackRock | 3.59% |
| 3 | MARSHALL WACE, LLP | 2.24% |
| 4 | Stonepine Capital Management, LLC | 2.04% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.74% |
| 6 | State Street | 1.67% |
| 7 | PARAMETRIC PORTFOLIO ASSOCIATES LLC | 1.63% |
| 8 | DE Shaw | 0.98% |
| 9 | Renaissance | 0.74% |
| 10 | Northern Trust | 0.73% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 3,494,068 | 16.38% | Schedule 13G, filed November 7, 2025 |
| Dapice Joshua J. | 2,816,862 | 13.20% | Schedule 13G, filed February 5, 2026 |
| Farallon Capital Management, LLC | 2,108,262 | 9.88% | Proxy statement (DEF 14A), proxy filed January 27, 2025 |
| BlackRock | 2,018,669 | 9.46% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 2,007,433 | 9.41% | Form 13F, quarter ended March 31, 2025 |
| Jay R. Luly, Ph.D. | 1,703,616 | 7.99% | Schedule 13D, filed February 14, 2025 |
| Krensavage Asset Management, LLC | 1,498,074 | 7.02% | Proxy statement (DEF 14A), proxy filed January 27, 2025 |
| Millennium Management | 1,346,932 | 6.31% | Form 13F, quarter ended March 31, 2025 |
| Morgan Stanley | 1,102,852 | 5.17% | Proxy statement (DEF 14A), proxy filed January 27, 2025 |
| Integrated Core Strategies (US) LLC | 665,953 | 3.12% | Schedule 13G, filed January 20, 2026 |
Percentages above are of 21,332,544 shares outstanding, as reported by ENANTA PHARMACEUTICALS INC. on its Form 10-Q dated February 4, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ENANTA PHARMACEUTICALS INC.'s shareholder meeting held March 13, 2025, in the 2024-2025 proxy season, 130 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,175 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation paid to our named executive officers, as… — ENANTA PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ENANTA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on March 17, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ENANTA PHARMACEUTICALS INC.’s 10-Q dated February 4, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ENANTA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “ENANTA PHARMACEUTICALS (ENTA) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/enanta-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.